- Organon ( NYSE: OGN ) said Ontruzant, a biosimilar of Roche's ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) cancer drug Herceptin, to treat Canadian adults with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) was now available in Canada.
- Organon said Ontruzant was developed and manufactured by its collaborator Samsung Bioepis.
- The company said Ontruzant represents Organon Canada's second oncology product available for patients with certain forms of cancers.
For further details see:
Organon launches biosimilar of cancer drug Herceptin in Canada